Treatment for Charcot-Marie-Tooth disease

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Young, Peter ^a   De Jonghe, P ^b   Stogbauer F ^b   Butterfass Bahloul, T ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; GANGLIOSIDE; NEUROTROPHIN 3; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEMYELINATING DISEASE; EXERCISE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MOTOR NEUROPATHY; NERVE FIBER DEGENERATION; ORTHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSORY NEUROPATHY; SYSTEMATIC REVIEW;

EID: 44349127652     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006052.pub2     Document Type: Review

References (88)

1. Bradley 1988 {published data only} Bradley WG, Badger GJ, Tandan R, Fillyaw MJ, Young J, Fries TJ, et al.Double-blind controlled trials of Cronassial in chronic neuromuscular diseases and ataxia. Neurology 1988;38(11):1731-1739. [MEDLINE: 1849].
2. Burns 2006 {published and unpublished data} Burns J, Crosbie J, Ouvrier R, Hunt A. Effective orthotic therapy for the painful cavus foot: a randomized controlled trial. Journal of the American Podiatric Medical Association 2006;96(3):205-211. [MEDLINE: 2].
3. Chetlin 2004 {published and unpublished data} Chetlin RD, Gutmann L, Tarnopolsky MA, Ullrich IH, Yeater RA. Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease. Muscle & Nerve 2004;30(1):69-76. [MEDLINE: 336].
4. Doherty 2001 {published and unpublished data} Doherty TJ, Lougheed K, Markez J, Tarnopolsky MA. Creatine monohydrate does not increase strength in patients with hereditary neuropathy. Neurology 2001;57(3):559-60. [MEDLINE: 728].
5. Lindeman 1995 {published and unpublished data} Lindeman E, Leffers P, Spaans F, Drukker J, Reulen J, Kerckhoffs M, et al.Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: a randomized clinical trial. Archives of Physical and Medical Rehabilitation 1995;76(7):612-20. [MEDLINE: 2102].
6. Lindeman 1999 {published and unpublished data} Lindeman E, Spaans F, Reulen J, Leffers P, Drukker J. Progressive resistance training in neuromuscular patients. Effects on force and surface EMG. Journal of Electromyography and Kinesiology 1999;9(6): 379-84. [MEDLINE: 913].
7. Lindemann 1994 {published data only} Lindeman E, Drukker J. Specificity of strength training in neuromuscular disorders. Journal of Rehabilitation Sciences 1994;7(Suppl.):13-15.
8. Sahenk 2005 {published and unpublished data} Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML, Cedarbaum JM, et al.NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 2005;65(5):681-9.
9. Smith 2006 {published and unpublished data} Smith CA, Chetlin RD, Gutmann L, Yeater RA, Alway SE. Effects of exercise and creatine on myosin heavy chain isoform composition in patients with Charcot-Marie-Tooth disease. Muscle & Nerve 2006; 34(5):586-94. [MEDLINE: 1].
10. Aras 2005 Aras O, Karaduman A, Yilmaz O, Basoglu B. The effect of electrical stimulation on muscle strength in neuromuscular diseases. [Turkish]. Fizyoterapi Rehabilitasyon Vol 16(2)()(pp 45-50), 2005 2005;16(2):45-50. [MEDLINE: 275].
11. Bean 2001 Bean J, Walsh A, Frontera W. Brace modification improves aerobic performance in Charcot-Marie-Tooth disease: a single-subject design. American Journal of Physical Medicine and Rehabilitation 2001;80(8):578-82. [MEDLINE: 742].
12. Brown 1992 Brown RE, Zamboni WA, Zook EG, Russell RC. Evaluation and management of upper extremity neuropathies in Charcot-Marie-Tooth disease. Journal of Hand Surgery 1992;17(3):523-30. [MEDLINE: 1654].
13. Chetlin 2004b Chetlin RD, Gutmann L, Tarnopolsky M, Ullrich IH, Yeater RA. Resistance training effectiveness in patients with Charcot-Marie-Tooth disease: recommendations for exercise prescription. Archive of Physical Medicine and Rehabilitation 2004;85(8):1217- 23.
14. Congia 1991 Congia S, Tronci S, Ledda M, Porcella A, Coppola G. Low doses of TRH in amyotrophic lateral sclerosis and in other neurological diseases. Italian Journal of Neurological Sciences 1991;12(2):193- 8. [MEDLINE: 1735].
15. Dahl 2004 Dahl A, Skjeldal OH, Simensen A, Dalen HE, Brathen T, Ahlvin P, et al.[Treatment of patients with neuromuscular disease in a warm climate]. Tidsskr Nor Laegeforen 2004;124(13-14):1795-8. [MEDLINE: 334].
16. de Matas 2000 de Matas M, Francis P, Miles JB. Microvascular decompression for trigeminal neuralgia in Charcot-Marie-Tooth disease. Journal of Neurosurgery 2000;92(4):715-7. [MEDLINE: 885].
17. Dyck 1982a Dyck PJ, Swanson CJ, Low PA, Bartleson JD, Lambert EH. Prednisone-responsive hereditary motor and sensory neuropathy. Mayo Clinic Proceedings 1982;57(4):239-46.
18. Dyck 1982b Dyck PJ, Swanson CJ, Low PA. Prednisone-responsive hereditary motor and sensory neuropathy. Neurology 1982;32(4II): 710.
19. Folkers 1985 Folkers K, Wolaniuk J, Simonsen R, Morishita M, Vadhanavikit S. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proceedings of the National Academy of Sciences of the United States of America 1985;82(13):4513- 6. [MEDLINE: 1937].
20. Folkers 1995 Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochimica et Biophysica Acta 1995;1271(1):281-6. [MEDLINE: 1381].
21. Jaradeh 1992 Jaradeh S, Dyck PJ. Hereditary motor and sensory neuropathy with treatable extrapyramidal features. Archives of Neurology 1992;49(2):175-8.
22. Lindeman 1994b Lindeman E, Leffers P, Reulen J, Spaans F, Drukker J. Reduction of knee torques and leg-related functional abilities in hereditary motor and sensory neuropathy. Archives of Physical Medicine and Rehabilitation 1994;75(11):1201-5. [MEDLINE: 1436].
23. Lindeman 1998 Lindeman E, Leffers P, Reulen J, Spaans F, Drukker J. Quadriceps strength and timed motor performances in myotonic dystrophy, Charcot-Marie-Tooth disease, and healthy subjects. Clinical rehabilitation 1998;12(2):127-35. [MEDLINE: 1070].
24. Lindeman 1999b Lindeman E, Spaans F, Reulen JP, Leffers P, Drukker J. Surface EMG of proximal leg muscles in neuromuscular patients and in healthy controls. Relations to force and fatigue. Journal of Electromyography and Kinesiology 1999;9(5):299-307. [MEDLINE: 927].
25. Lissett 1998 Lissett CA, Toogood AA, Didi M, Shalet SM. Growth hormone replacement in an adult with mild growth hormone deficiency and hereditary motor and sensory neuropathy: growth hormone restores independent mobility. Hormone Research 1998;50(4):232-6.
26. Lobzin 1986 Lobzin VS, Saikova LA, Kosachev VD. Pathogenesis and treatment of neural amyotrophy [Russian]. Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 1986;86(11):1629-33. [MEDLINE: 6387].
27. Lobzin 1987 Lobzin VS, Saikova LA, Kosachev VD, Shiman AG. [Physical therapy of hereditary neuropathies]. Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 1987;87(3):342-5. [MEDLINE: 1903].
28. Lobzin 1988 Lobzin VS, Saikova LA, Shiman AG, Kosachev VD. [Treatment of patients with Charcot-Marie-Tooth neural amyotrophy]. Vrach Delo 1988;Dec.(12):73-4. [MEDLINE: 1846].
29. Lobzin 1990 Lobzin VS, Saikova LA, Shiman AG, Kosachev VD. [A comparative evaluation of the efficacy of physical treatment methods in Charcot-Marie-Tooth neural amyotrophy]. Vopr Kurortol Fizioter Lech Fiz Kult 1990;Nov-Dec(6):53-6. [MEDLINE: 1758].
30. Lobzin 1992 Lobzin VS, Zhulev NM, Kosachev VD, Tiukarkina AB, Badzgaradze I, Zavolokov IG. [Autonomic vascular disorders in neuropathies and the methods for their pathogenetic therapy]. Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 1992;92(5-12):32-5. [MEDLINE: 1682].
31. Mann 1992 *Mann DC, Hsu JD. Triple arthrodesis in the treatment of fixed cavovarus deformity in adolescent patients with Charcot-Marie-Tooth disease. Foot & Ankle 1992;13(1):1-6. [MEDLINE: 1675].
32. Miller 1982 Miller GM, Hsu JD, Hoffer MM, Rentfro R. Posterior tibial tendon transfer: a review of the literature and analysis of 74 procedures. Journal of Pediatric Orthopedics 1982;2(4):363-70. [MEDLINE: 1991].
33. Oganesyan 1996 Oganesyan OV, Istomina IS, Kuzmin VI. Treatment of equinocavovarus deformity in adults with the use of a hinged distraction apparatus. The Journal of Bone and Joint Surgery. American Volume 1996;78(4):546-56. [MEDLINE: 1290].
34. Prensky 1984 Prensky AL, Dodson WE. The steroid treatment of hereditary motor and sensory neuropathy. Neuropediatrics 1984;15(4):203-7. [MEDLINE: 1956].
35. Riley 1980 Riley WB, Mann RJ, Burkhalter WE. Extensor pollicis longus opponensplasty. Journal of Hand Surgery [Am.] 1980;5(3): 217-20.
36. Russell 1995 Russell JW, Windebank AJ, Harper CM. Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine. Mayo Clinic Proceedings 1995;70(6):532-39. [MEDLINE: 1378].
37. Saltzman 1999 Saltzman CL, Fehrle MJ, Cooper RR, Spencer EC, Ponseti IV. Triple arthrodesis: twenty-five and forty-four-year average follow-up of the same patients. The Journal of Bone and Joint Surgery. American Volume 1999;81(10):1391-1402. [MEDLINE: 6388].
38. Trumble 1999 Trumble SJ, Mayo KA, Mast JW. The periacetabular osteotomy. Minimum 2 year followup in more than 100 hips. Clinical Orthopaedics and Related Research 1999;363:54-63.
39. Wetmore 1989 Wetmore RS, Drennan JC. Long-term results of triple arthrodesis in Charcot-Marie-Tooth disease. The Journal of Bone and Joint Surgery. American Volume 1989;71(3):417-22. [MEDLINE: 1832].
40. Williams 1986 Williams LL, O'Dougherty MM, Wright FS, Bobulski RJ, Horrocks LA. Dietary essential fatty acids, vitamin E, and Charcot-Marie-Tooth disease. Neurology 1986;36(9):1200-1205. [MEDLINE: 1911].
41. Wood 1995 Wood VE, Huene D, Nguyen J. Treatment of the upper limb in Charcot-Marie-Tooth disease. Journal of Hand Surgery (Edinburgh, Lothian) 1995;20(4):511-18. [MEDLINE: 1366].
42. Blin Information requested. Ongoing study Starting date of trial not provided. Contact author for more information.
43. Kurlemann Single center randomized double blind placebo controlled. Ongoing study September 2007.
44. Pareyson A multicenter, randomized, double-blind, placebo-controlled trial of long term ascorbic acid in Charcot-Marie-tooth disease type 1A (CMT-TRIAAL). Ongoing study Autumn 2006.
45. Shy A Randomized, placebo-controlled, double masked 120 subject "Futility Design" clinical trial of Ascorbic acid treatment of Charcot-Marie-Tooth Disease Type 1A.. Ongoing study April 2007.
46. Verhamme Ascorbic Acid Treatment in CMT1A Trial (AATIC). Ongoing study January 2006.
47. Adlkofer 1995 Adlkofer K, Martini R, Aguzzi A, Zielasek J, Toyka KV, Suter U. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nature Genetics 1995;11(3):274-80.
48. Adlkofer 1997 Adlkofer K, Frei R, Neuberg DH, Zielasek J, Toyka KV, Suter U. Heterozygous peripheral myelin protein 22-deficient mice are affected by a progressive demyelinating tomaculous neuropathy. Journal of Neuroscience 1997;17(12):4662-71.
49. Anderson 1996 Anderson RT, Aaronson NK, Bullinger M, McBee WL. A review of the progress towards developing health-related quality-of-life instruments for international clinical studies and outcomes research. Pharmacoeconomics 1996;10(4):336-55.
50. Cornblath 1999 Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, et al.Total neuropathy score: validation and reliability study. Neurology 1999;53(8):1660-4.
51. Dyck 2005a Shy ME, Lupski JR, Chance PF, Klein CJ, Dyck PJ. Hereditary Motor And Sensory Neuropathy. In: DyckPJ, ThomasPK editor(s). Peripheral Neuropathy. Vol. 2, Philadelphia: WB Saunders, 2005:1623-58.
52. Dyck 2005b Dyck PJ, Hughes RAC, O'Brien PC. Quantitating overall neuropathic symptoms, impairments, and outcomes. In: DyckPJ, ThomasPK editor(s). Peripheral Neuropathy. 4th Edition. Philadelphia: WB Saunders, 2005:1031-52.
53. Gabreels-Festen 1993 Gabreels-Festen A, Gabreels F. Hereditary demyelinating motor and sensory neuropathy. Brain Pathology 1993;3(2):135-46.
54. Grandis 2005 Grandis M, Shy ME. Current therapy for Charcot-Marie-Tooth disease. Current Treatment Options in Neurology 2005;7(1):23-31.
55. Hahn 2001 Hahn AF, Ainsworth PJ, Bolton CF, Bilbao JM, Vallat JM. Pathological findings in the x-linked form of Charcot-Marie-Tooth disease: a morphometric and ultrastructural analysis. Acta Neuropathologica (Berlin) 2001;101(2):129-39.
56. Harding 1980 Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980;103(2):259-80.
57. Hayasaka 1993a Hayasaka K, Himoro M, Takada G, Takahashi E, Minoshima S, Shimizu N. Structure and localization of the gene encoding human peripheral myelin protein 2 (PMP2). Genomics 1993;18:244-8.
58. Hayasaka 1993b Hayasaka K, Himoro M, Sawaishi Y, Nanao K, Takahashi T, Takada G, et al.De novo mutation of the myelin Po gene in Dejerine-Sottas disease (hereditary motor and sensory neuropathy type III). Nature Genetics 1993;5:266-8.
59. Hayasaka 1993c Hayasaka K, Ohnishi A, Takada G, Fukushima Y, Murai Y. Mutation of the myelin P0 gene in Charcot-Marie-tooth neuropathy type 1. Biochemical and Biophysical Research Communications 1993;194(3): 1317-22.
60. Jenkinson 1993 Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. British Medical Journal 1993;306(6890):1437-40.
61. Krajewski 1999 Krajewski K, Turansky C, Lewis R, Garbern J, Hinderer S, Kamholz J, et al.Correlation between weakness and axonal loss in patients with CMT1A. Annals of the New York Academy of Science 1999;883:490-2.
62. Krajewski 2000 Krajewski KM, Lewis RA, Fuerst DR, Turansky C, Hinderer SR, Garbern J, et al.Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000;123(Pt 7):1516-27.
63. Kuhlenbaumer 2002 Kuhlenbaumer G, Young P, Hunermund G, Ringelstein B, Stogbauer F. Clinical features and molecular genetics of hereditary peripheral neuropathies. Journal of Neurology 2002;249(12):1629-50.
64. Lupski 1991 Lupski J, de Oca-Luna R, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, et al.DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991;66(2):219-32.
65. Lupski 1992 Lupski J, Wise C, Kuwano A, Pentao L, Parke J, Glaze DG, et al.Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A. Nature Genetics 1992;1(1):29-33.
66. Martini 1997 Martini R. Animal models for inherited peripheral neuropathies. Journal of Anatomy 1997;191(Pt 3):321-36.
67. Martini 2000 Martini R. Animal models for inherited peripheral neuropathies: chances to find treatment strategies?. Journal of Neuroscience Research 2000;61(3):244-50.
68. Martini 2001 Martini R. The effect of myelinating Schwann cells on axons. Muscle & Nerve 2001;24(4):456-66.
69. Maurer 2002 Maurer M, Kobsar I, Berghoff M, Schmid CD, Carenini S, Martini R. Role of immune cells in animal models for inherited neuropathies: facts and visions. Journal of Anatomy 2002;200(4):405-14.
70. Merkies 2000 Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 2000;54(4):943-9.
71. Nelis 1996 Nelis E, Van Broeckhoven C, De Jonghe P, Lofgren A, Vandenberghe A, Latour P, et al.Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. European Journal of Human Genetics 1996;4(1):25-33.
72. Nicholson 1993 Nicholson G, Nash J. Intermediate nerve conduction velocities define X-linked Charcot-Marie-Tooth neuropathy families. Neurology 1993;43(12):2558-64.
73. Pareyson 2004 Pareyson D. Differential diagnosis of Charcot-Marie-Tooth disease and related neuropathies. Neurological Science 2004;52(2):72-82.
74. Pareyson 2006 Pareyson D, Schenone A, Fabrizi GM, Santoro L, Padua L, Quattrone A, et al.Amulticenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27]. Pharmacological Research 2006;54(6):436-41.
75. Passage 2004 Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, et al.Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nature Medicine 2004;10(4):396-401.
76. Reilly 2006 Reilly MM, de Jonghe P, Pareyson D. 136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands. Neuromuscular Disorders 2006;16(6):396-402.
77. Sereda 2003 Sereda MW, Meyer zu Horste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in amodel of Charcot-Marie-Tooth disease (CMT-1A). Nature Medicine 2003;9(12):1533-7.
78. Shy 2005 Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, et al.Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005;64(7):1209-14.
79. Street 2003 Street VA, Bennett CL, Goldy JD, Shirk AJ, Kleopa KA, Tempel BL, et al.Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot- Marie-Tooth disease 1C. Neurology 2003;60(1):22-6.
80. Suter 2003 Suter U, Scherer SS. Disease mechanisms in inherited neuropathies. Nature Reviews Neuroscience 2003;4(9):714-26.
81. Timmerman 1992 Timmerman V, Nelis E, Van Hul W, Nieuwenhuijsen B, Chen K, Wang S, et al.The peripheral myelin protein gene PMP-22 is contained within the Charcot-Marie-Tooth disease type 1A duplication. Nature Genetics 1992;1(3):171-5.
82. van der Kooi 2005 van der Kooi EL, Lindeman E, Riphagen I. Strength training and aerobic exercise training for muscle disease. Cochrane Database of Systematic Reviews 2005;The Cochrane Database of Systematic Reviews 2005(1):CD003907. [MEDLINE: 1].
83. van Swieten 1988 van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19(5):604-7.
84. Verhoeven 2006 Verhoeven K, Claeys KG, Zuchner S, Schroder JM, Weis J, Ceuterick C, et al.MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain 2006;129(Pt 8):2093-102.
85. White 2004 White CM, Pritchard J, Turner-Stokes L. Exercise for people with peripheral neuropathy. Cochrane Database of Systematic Reviews 2004, Issue 4.Art. No.: CD003904. DOI: 10.1002/14651858.CD003904. pub2.[MEDLINE: 8].
86. Young 2001 Young P, Suter U. Disease mechanisms and potential therapeutic strategies in Charcot-Marie-Tooth disease. Brain Research. Brain Research Reviews 2001;36(2-3):213-21.
87. Young 2003 Young P, Suter U. The causes of Charcot-Marie-Tooth disease. Cellular and Molecular Life Sciences 2003;60(12):2547-60.
88. Zuchner 2004 Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, et al.Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nature Genetics 2004;36(5):449-51.